The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO MAP 2022 | HEVs and lymphocyte recruitment in tumors in response to immune checkpoint blockade
Jean-Philippe Girard, PhD, CNRS-Université de Toulouse III, Toulouse, France, discusses the mediation of lymphocyte entry into tumors via tumor-associated high endothelial venules (HEVs). Using murine mouse models, tumor-associated HEVs (TA-HEVs) were demonstrated to be significant sites of lymphocyte entry into tumors at baseline and upon treatment with anti-PD-1/anti-CTLA-4 immune checkpoint blockade. Analysis of tumor biopsies from patients with metastatic melanoma revealed TA-HEVs are predictive of better response to the combination of anti-PD-1 and anti-CTLA-4 treatment. This interview took place at the Molecular Analysis for Precision oncology (MAP) Congress 2022 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
